EMA — authorised 7 January 2021
- Marketing authorisation holder: STEMLINE THERAPEUTICS B.V.
- Status: approved
EMA authorised Molecule 129 on 7 January 2021
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. EMA authorised it on 7 January 2021.
STEMLINE THERAPEUTICS B.V. holds the EU marketing authorisation.